Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AI-081 PD-1/VEGF bispecific antibody in advanced solid tumors
ChiCTR2600125390Phase 2Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- May 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cesalatamig in Nonhematologic neoplasms, colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and 3 more (10 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoints: Part A: Maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), Part A: Incidence of treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs) and 2 more. Started May 2026; status: recruiting.
02
Drugs
cesalatamig
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on ChiCTR2600125390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125390.